EIF2A and Parkinson disease: Postmortem studies in patients with Alzheimer’s disease, Parkinson’s disease, progressive supranuclear palsy, and ALS [29,30,31] reveal markers of UPR activation, including phosphorylation of PERK and eIF2α associated with protein aggregates [32,33] (Figure 1).